CCR2

C-C chemokine receptor type 2 (CCR2), also designated CD192 or CC-CKR2, is a G protein-coupled receptor primarily expressed on monocytes, macrophages, and memory T cells. It binds multiple ligands, including CCL2 (MCP-1), CCL7, and CCL13, mediating leukocyte migration to inflammatory sites via calcium signaling and MAPK/ERK pathway activation. CCR2 interacts with JAK/STAT and PI3K/AKT cascades, modulating immune responses and tissue remodeling. Its pivotal role in inflammatory cell infiltration positions it as a key player in chronic inflammatory disorders, cancer metastasis, and metabolic dysregulation.
Dysregulated CCR2 signaling is implicated in atherosclerosis, rheumatoid arthritis, non-alcoholic steatohepatitis (NASH), and neuropathic pain. Pharmaceutical targeting has focused on small-molecule antagonists (e.g., CCX140, PF-04634817) and monoclonal antibodies to disrupt CCR2-CCL2 axis. Several candidates demonstrated phase II efficacy in diabetic nephropathy and fibrosis but faced challenges in achieving clinical endpoints for NASH. Dual CCR2/5 inhibitors like cenicriviroc showed promise in HIV-associated comorbidities, while combination therapies with checkpoint inhibitors are being explored in oncology trials. Structural optimization continues to address pharmacokinetic limitations and receptor selectivity.